Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level

被引:5
作者
Marsik, C [1 ]
Halama, T [1 ]
Cardona, F [1 ]
Schlifke, I [1 ]
Mittermayer, F [1 ]
Jilma, B [1 ]
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, Div Hematol & Immunol, A-1090 Vienna, Austria
关键词
endotoxin; IL-6; gp130; CD126; RT-PCR;
D O I
10.1016/j.clim.2004.11.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin 6 (IL-6) performs a prominent role during sepsis. To examine the molecular regulation of IL-6, IL-6 receptor, and signaling receptor gp130 during endotoxemia, nine healthy young volunteers received a bolus injection of lipopolysaccharide (LPS) on day 1 and saline on day 2 in a double blind, randomized, placebo-controlled trial. LPS enhanced IL-6 release 300-fold. IL-6 mRNA expression was not significantly altered in blood samples at any time after LPS infusion in vivo, while incubation of whole blood with 50 pg/ml LPS up-regulated IL-6 mRNA levels 8000- to 50,000-fold in vitro. LPS infusion increased synthesis of gp 130 mRNA 5.5-fold compared to baseline at 4 h (P < 0.05), while no significant change was observed in the placebo period (P = 0.001 between groups). LPS increased the percentage of gp130 positive neutrophils gp130 700% over baseline at 8 h (P < 0.01 versus baseline and placebo). IL-6 receptor levels were not significantly altered by low-grade endotoxernia. In conclusion, endotoxemia up-regulates gp 130 expression in vivo and in vitro. Quantification of IL-6 mRNA expression in circulating leukocytes is unlikely a suitable marker for monitoring of endotoxemia. (C) 2004 Published by Elsevier Inc.
引用
收藏
页码:293 / 298
页数:6
相关论文
共 18 条
[1]   Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans [J].
Dekkers, PEP ;
Juffermans, NP ;
ten Hove, T ;
de Jonge, E ;
van Deventer, SJH ;
van der Poll, T .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1055-1061
[2]   DOWN-REGULATION OF PROINFLAMMATORY CYTOKINE RELEASE IN WHOLE-BLOOD FROM SEPTIC PATIENTS [J].
ERTEL, W ;
KREMER, JP ;
KENNEY, J ;
STECKHOLZER, U ;
JARRAR, D ;
TRENTZ, O ;
SCHILDBERG, FW .
BLOOD, 1995, 85 (05) :1341-1347
[3]   CHARACTERIZATION OF INTERLEUKIN-1 AND INTERLEUKIN-6 PRODUCTION BY HEPATIC ENDOTHELIAL-CELLS AND MACROPHAGES [J].
FEDER, LS ;
TODARO, JA ;
LASKIN, DL .
JOURNAL OF LEUKOCYTE BIOLOGY, 1993, 53 (02) :126-132
[4]   Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis [J].
Harbarth, S ;
Holeckova, K ;
Froidevaux, C ;
Pittet, D ;
Ricou, B ;
Grau, GE ;
Vadas, L ;
Pugin, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (03) :396-402
[5]   Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway [J].
Heinrich, PC ;
Behrmann, I ;
Müller-Newen, G ;
Schaper, F ;
Graeve, L .
BIOCHEMICAL JOURNAL, 1998, 334 :297-314
[6]   Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils [J].
Hollenstein, U ;
Homoncik, M ;
Stohlawetz, PJ ;
Marsik, C ;
Sieder, A ;
Eichler, HG ;
Jilma, B .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01) :343-346
[7]   Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans [J].
Jilma, B ;
Marsik, C ;
Mayr, F ;
Graninger, MT ;
Taylor, FB ;
Ribel, MC ;
Erhardtsen, E ;
Handler, S ;
Eichler, HG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :403-410
[8]   Interleukin 6 and haemostasis [J].
Kerr, R ;
Stirling, D ;
Ludlam, CA .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :3-12
[9]  
Kremer JP, 1996, ACTA HAEMATOL-BASEL, V95, P268
[10]   Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans [J].
Marsik, C ;
Halama, T ;
Cardona, F ;
Wlassits, W ;
Mayr, F ;
Pleiner, J ;
Jilma, B .
SHOCK, 2003, 20 (06) :493-496